EP3307305A4 - Targeted adaptive vaccines - Google Patents

Targeted adaptive vaccines Download PDF

Info

Publication number
EP3307305A4
EP3307305A4 EP16808481.2A EP16808481A EP3307305A4 EP 3307305 A4 EP3307305 A4 EP 3307305A4 EP 16808481 A EP16808481 A EP 16808481A EP 3307305 A4 EP3307305 A4 EP 3307305A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
targeted adaptive
adaptive
targeted
adaptive vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16808481.2A
Other languages
German (de)
French (fr)
Other versions
EP3307305A1 (en
Inventor
Eric YI-CHUN HUANG
Stephen Hoge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of EP3307305A1 publication Critical patent/EP3307305A1/en
Publication of EP3307305A4 publication Critical patent/EP3307305A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16808481.2A 2015-06-10 2016-06-10 Targeted adaptive vaccines Withdrawn EP3307305A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173783P 2015-06-10 2015-06-10
PCT/US2016/037095 WO2016201377A1 (en) 2015-06-10 2016-06-10 Targeted adaptive vaccines

Publications (2)

Publication Number Publication Date
EP3307305A1 EP3307305A1 (en) 2018-04-18
EP3307305A4 true EP3307305A4 (en) 2019-05-22

Family

ID=57504553

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16808481.2A Withdrawn EP3307305A4 (en) 2015-06-10 2016-06-10 Targeted adaptive vaccines

Country Status (2)

Country Link
EP (1) EP3307305A4 (en)
WO (1) WO2016201377A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013154295A (en) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. COMPOSITIONS OF LIPID NANOPARTICLES AND METHODS FOR DELIVERY OF mRNA
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
ES2882110T3 (en) 2013-03-14 2021-12-01 Translate Bio Inc Methods and Compositions for Delivering mRNA-Encoded Antibodies
ES2708561T3 (en) 2013-03-14 2019-04-10 Translate Bio Inc Methods for the purification of messenger RNA
LT2968586T (en) 2013-03-14 2018-11-26 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
DK3388834T3 (en) 2013-03-15 2020-05-04 Translate Bio Inc SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS BY MIXED FORMULATIONS
CA2928186A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
EP3134131B1 (en) 2014-04-23 2021-12-22 ModernaTX, Inc. Nucleic acid vaccines
CN117402871A (en) 2014-04-25 2024-01-16 川斯勒佰尔公司 Method for purifying messenger RNA
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
TW201718638A (en) 2015-07-21 2017-06-01 現代治療公司 Infectious disease vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
MA46316A (en) 2015-10-22 2021-03-24 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
JP2018531290A (en) 2015-10-22 2018-10-25 モデルナティーエックス， インコーポレイテッド Sexually transmitted disease vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
PE20181529A1 (en) 2015-10-22 2018-09-26 Modernatx Inc NUCLEIC ACID VACCINES FOR VARICELA-ZOSTER VIRUS (VZV)
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3825400A1 (en) 2016-04-08 2021-05-26 Translate Bio Ma, Inc. Multimeric coding nucleic acid and uses thereof
KR102533456B1 (en) 2016-05-18 2023-05-17 모더나티엑스, 인크. Polynucleotides encoding relaxin
EP3842530A1 (en) 2016-06-13 2021-06-30 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
RU2768829C2 (en) * 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Anticancer rna vaccines
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
US20200368162A1 (en) * 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. Methods for hplc analysis
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
CN111315359A (en) 2017-08-31 2020-06-19 摩登纳特斯有限公司 Method for preparing lipid nanoparticles
MA50253A (en) 2017-09-14 2020-07-22 Modernatx Inc ZIKA VIRUS RNA VACCINES
WO2019126593A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019178759A1 (en) * 2018-03-21 2019-09-26 维多利亚生物医学控股股份有限公司 Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
KR20210060480A (en) 2018-08-24 2021-05-26 트랜슬레이트 바이오 인코포레이티드 Method for purifying messenger RNA
EP3844154A1 (en) 2018-08-31 2021-07-07 Massachusetts Institute of Technology Ionizable lipidoids and their uses
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
KR20210142636A (en) 2019-02-20 2021-11-25 모더나티엑스, 인크. RNA polymerase variants for co-transcriptional capping
KR20220132583A (en) * 2020-01-28 2022-09-30 유나이티드 바이오메디칼 인크. Peptide immunogens targeting PCSK9 and formulations thereof for the prevention and treatment of PCSK9 mediated disorders
CN113521269A (en) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206852A1 (en) * 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides
WO2015024666A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating lung cancer
WO2015085318A2 (en) * 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010106187A2 (en) * 2009-03-20 2010-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206852A1 (en) * 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides
WO2015024666A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating lung cancer
WO2015085318A2 (en) * 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GERGANA GALABOVA ET AL: "Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management", PLOS ONE, vol. 9, no. 12, 4 December 2014 (2014-12-04), pages e114469, XP055579730, DOI: 10.1371/journal.pone.0114469 *
NORBERT PARDI ET AL: "mRNA vaccines - a new era in vaccinology", NATURE REVIEWS. DRUG DISCOVERY, vol. 17, no. 4, 12 January 2018 (2018-01-12), GB, pages 261 - 279, XP055524319, ISSN: 1474-1776, DOI: 10.1038/nrd.2017.243 *
PATRICK MIDOUX ET AL: "Lipid-based mRNA vaccine delivery systems", EXPERT REVIEW OF VACCINES, vol. 14, no. 2, 12 February 2015 (2015-02-12), GB, pages 221 - 234, XP055439935, ISSN: 1476-0584, DOI: 10.1586/14760584.2015.986104 *
S. HOLTKAMP ET AL: "Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells", BLOOD, vol. 108, no. 13, 15 December 2006 (2006-12-15), pages 4009 - 4017, XP055044965, ISSN: 0006-4971, DOI: 10.1182/blood-2006-04-015024 *
See also references of WO2016201377A1 *
TOMPKINS STEPHEN MARK ET AL: "Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1", EMERGING INFECTIOUS DISE, EID, ATLANTA, GA, US, vol. 13, no. 3, 1 March 2007 (2007-03-01), pages 426 - 435, XP009089369, ISSN: 1080-6040 *

Also Published As

Publication number Publication date
WO2016201377A1 (en) 2016-12-15
EP3307305A1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
EP3307305A4 (en) Targeted adaptive vaccines
EP3076994A4 (en) Targeted adaptive vaccines
EP3328873A4 (en) Targeted oligonucleotides
EP3197057A4 (en) Transceiver
EP3309424A4 (en) Damper
EP3309423A4 (en) Damper
EP3312431A4 (en) Blower
EP3231644A4 (en) Stabilizer
EP3196502A4 (en) Damper
EP3351820A4 (en) Damper
EP3296588A4 (en) Damper
EP3164840A4 (en) Enhanced near field communications attachment
EP2938045B8 (en) Geopositioning method
EP3706787A4 (en) Vaccine
EP3299636A4 (en) Blower
EP3327473A4 (en) Mode scrambler
EP3171052A4 (en) Damper
AU2017904499A0 (en) Vaccine
AU2017900446A0 (en) Vaccine
AU2016902014A0 (en) Vaccine
EP3290048A4 (en) Immunity-inducing agent
AU2015901481A0 (en) Schistosoma vaccine
AU2015902954A0 (en) Totally adjustable wingsail
AU2015903147A0 (en) FoLine
AU2015902786A0 (en) SafeStick

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190423

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/31 20060101ALI20190415BHEP

Ipc: A61K 39/00 20060101AFI20190415BHEP

Ipc: A61P 3/06 20060101ALI20190415BHEP

Ipc: C12N 9/52 20060101ALI20190415BHEP

Ipc: G01N 33/569 20060101ALI20190415BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191121